Literature DB >> 24101025

"Cherry picking", a multiple non-anatomic liver resection technique, as a promising option for diffuse liver metastases in patients with neuroendocrine tumours.

Markus Krausch1, Andreas Raffel, Martin Anlauf, Matthias Schott, Nadja Lehwald, Andreas Krieg, Stefan Andreas Topp, Kenko Cupisti, Wolfram Trudo Knoefel.   

Abstract

INTRODUCTION: Liver metastases of GEP-NETs are a known major prognostic factor with a strong effect on patients' survival. To date, various treatment options are available, whereas surgery remains the only curative option. Because large liver resections often cannot be performed due to insufficient remnant liver volume, a special operative technique, "cherry picking" (multiple nonanatomic liver resections), can be used as a tissue-preserving procedure.
METHODS: Of 91 patients with various GEP-NETs, 16 patients were identified with synchronous or metachronous multifocal, bilobular liver metastases (>10). All were treated with "cherry picking." Patient records were reviewed retrospectively and clinical data and pathology results were analyzed.
RESULTS: Mean survival after primary tumour resection was 82.8 versus 41.2 months after liver surgery. All 16 patients are still alive. Mean recurrence-free survival after primary tumour operation was 49.8 versus 24.6 months after liver surgery. Complications of cherry picking included two postoperative biliary leakages and three small hepatic abscesses (conservative/interventional approach 25 % (n = 4), surgical approach 6.25 % (n = 1). There was no postoperative mortality. Initial hormonal symptoms (5/16 patients) completely disappeared postoperatively in 2 patients and were significantly decreased in 3 patients.
CONCLUSIONS: The tissue-preserving surgical technique "cherry picking" has developed due to improved imaging techniques and increased knowledge in liver anatomy, which has helped to make this approach safer and easier. Highly selected patients with multiple bilobular liver metastases of GEP-NET can benefit from this special surgical approach, also applicable for recurrent metastases.

Entities:  

Mesh:

Year:  2014        PMID: 24101025     DOI: 10.1007/s00268-013-2267-3

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  49 in total

Review 1.  Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

Authors:  U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann
Journal:  Neuroendocrinology       Date:  2005-04-18       Impact factor: 4.914

Review 2.  Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics.

Authors:  Guido Rindi; Cesare Bordi
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-08       Impact factor: 3.043

3.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

Review 4.  Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?

Authors:  Pamela J Hodul; Jonathan R Strosberg; Larry K Kvols
Journal:  Cancer Control       Date:  2008-10       Impact factor: 3.302

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

7.  Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Authors:  Karl Y Bilimoria; Mark S Talamonti; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

8.  Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan Strosberg; Nancy Gardner; Larry Kvols
Journal:  Pancreas       Date:  2009-04       Impact factor: 3.327

9.  7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly.

Authors:  Eduardo A Perez; Leonidas G Koniaris; Sarah E Snell; Juan C Gutierrez; William E Sumner; David J Lee; Nicole C Hodgson; Alan S Livingstone; Dido Franceschi
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 10.  Neuroendocrine tumors of the pancreas.

Authors:  Florian Ehehalt; Hans D Saeger; C Max Schmidt; Robert Grützmann
Journal:  Oncologist       Date:  2009-05-01
View more
  7 in total

1.  Superselective intra-arterial hepatic injection of indocyanine green (ICG) for fluorescence image-guided segmental positive staining: experimental proof of the concept.

Authors:  Michele Diana; Yu-Yin Liu; Raoul Pop; Seong-Ho Kong; Andras Legnèr; Remy Beaujeux; Patrick Pessaux; Luc Soler; Didier Mutter; Bernard Dallemagne; Jacques Marescaux
Journal:  Surg Endosc       Date:  2016-08-05       Impact factor: 4.584

2.  Colorectal cancer liver metastases within the central and peripheral segments: Parenchymal sparing surgery adaptation.

Authors:  A A Burlaka; A V Paliichuk; O I Iatsyna; О О Kolesnik
Journal:  Ann Med Surg (Lond)       Date:  2020-08-14

3.  Retrospective analysis of interventional treatment of hepatic metastasis from gastroenteropancreatic neuroendocrine tumors.

Authors:  Peng Liu; Xu Zhu; Jie Li; Ming Lu; Jiahua Leng; Ying Li; Jiangyuan Yu
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

Review 4.  Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

Authors:  Xinzhe Yu; Jichun Gu; Haoxuan Wu; Deliang Fu; Ji Li; Chen Jin
Journal:  J Oncol       Date:  2018-11-14       Impact factor: 4.375

5.  Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases.

Authors:  Yuzo Umeda; Takeshi Nagasaka; Kosei Takagi; Ryuichi Yoshida; Kazuhiro Yoshida; Tomokazu Fuji; Tatsuo Matsuda; Kazuya Yasui; Kenjiro Kumano; Hiroki Sato; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  Langenbecks Arch Surg       Date:  2021-11-27       Impact factor: 2.895

6.  Parenchyma-sparing strategy and oncological prognosis in patients with colorectal cancer liver metastases.

Authors:  A A Burlaka; D E Makhmudov; I I Lisnyi; A V Paliichuk; V V Zvirych; A V Lukashenko
Journal:  World J Surg Oncol       Date:  2022-04-17       Impact factor: 3.253

7.  Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Shunda Du; Jianjiao Ni; Linqian Weng; Fei Ma; Shaohua Li; Wenze Wang; Xinting Sang; Xin Lu; Shouxian Zhong; Yilei Mao
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.